- Amwell's stock almost doubled from its IPO and has since lost around 74% of its value.
- Up to $250 billion - or 20% - of current US healthcare spend could potentially be virtualized.
- For FY21, the management only expects revenue growth of up to 10% and fails to communicate any plan on reaching profitability let alone earning money.
- With an expected EV/Sales ratio of 6.4, Amwell is relatively fair priced but cannot keep up with its dominant market competitor who outshines Amwell in every metric.
For further details see:
Want To Play Telehealth? Amwell Shouldn't Be Your Pick